Neoleukin Therapeutics
Cash Flow
Last updated:
Cash flow statement presents a set of outflows and inflows of cash within a company through operating, investing and financing activities. Over the last year, operating activities of Neoleukin Therapeutics generated cash of -$45,607,000, which is more than the previous year. Cash used in financing activities reached the amount of $161,000 last year. Net change in cash is therefore -$104,580,000.
Cash Flow
| 2013 | -7.93M | -2.64M | 19.58M |
|---|---|---|---|
| 2014 | -17.80M | -23.57M | 45.27M |
| 2015 | -20.26M | -47.53M | 92.94M |
| 2016 | -30.22M | -48.05M | 71.11M |
| 2017 | -44.71M | 64.01M | 423K |
| 2018 | -31.57M | 55.95M | 570K |
| 2019 | -15.39M | -688K | 82.23M |
| 2020 | -24.57M | -2.21M | 77.13M |
| 2021 | -47.55M | -3.26M | 732K |
| 2022 | -45.60M | -59.13M | 161K |
NLTX Cash Flow Statement (2013 – 2022)
| 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | |
|---|---|---|---|---|---|---|---|---|---|---|
Cash at beginning of period | 143.34M | 193.43M | 143.09M | 76.92M | 52.03M | 32.30M | 39.52M | 14.90M | 11.00M | 2.00M |
Operating activities | ||||||||||
Net income | -57.55M | -60.69M | -33.27M | -69.44M | -31.58M | -50.18M | -37.00M | -21.86M | -24.02M | -8.72M |
| Adjustments to reconcile net income to cash generated by operating activities: | ||||||||||
Depreciation and amortization | 2.61M | 2.27M | 1.82M | 340K | 0 | 0 | 0 | 0 | 135.94K | 59.57K |
Stock-based compensation expense | 8.82M | 11.55M | 5.62M | 7.68M | 4.69M | 3.83M | 1.96M | 1.50M | 1.04M | 349.32K |
| Deferred income tax benefit | 8.82M | 11.55M | 5.62M | 7.68M | 4.69M | 3.83M | 1.96M | 1.50M | 1.04M | 349.32K |
| Changes in operating assets and liabilities: | ||||||||||
Accounts receivable, net | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 34K | -37.50K | 599 |
Inventories | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 450K | -3.61M | 0 |
Accounts payable | 2.25M | -142K | 3.01M | -2.24M | -6.47M | 1.82M | 4.81M | -450K | 3.61M | 0 |
Cash generated by operating activities | -45.60M | -47.55M | -24.57M | -15.39M | -31.57M | -44.71M | -30.22M | -20.26M | -17.80M | -7.93M |
Investing activities | ||||||||||
Purchases Of Investments | -107.52M | 0 | 0 | 0 | 0 | -5.99M | -106.44M | -60.70M | -36.47M | -2.82M |
Investments In Property Plant And Equipment | -1.11M | -3.26M | -2.21M | -879K | -49K | -494K | -713K | -27K | -113.89K | -11.74K |
Acquisitions Net | 0 | 0 | 0 | 191K | 0 | 0 | 0 | 0 | 0 | 0 |
Cash generated by investing activities | -59.13M | -3.26M | -2.21M | -688K | 55.95M | 64.01M | -48.05M | -47.53M | -23.57M | -2.64M |
Financing activities | ||||||||||
Common Stock Issued | 134K | 0 | 71.67M | 86.21M | 0 | 0 | 75.36M | 98.03M | 53.13M | 7 |
Payments for dividends | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Repurchases of common stock | 82K | 372K | 199K | 560K | 0 | 0 | 0 | 0 | -590 | 0 |
Repayments of term debt | 0 | -51K | -49K | 0 | -32K | 0 | -4K | 0 | -2.5M | 0 |
Cash used in financing activities | 161K | 732K | 77.13M | 82.23M | 570K | 423K | 71.11M | 92.94M | 45.27M | 19.58M |
Net Change In Cash | -104.58M | -50.08M | 50.34M | 66.16M | 24.89M | 19.73M | -7.22M | 24.62M | 3.89M | 9.00M |
Cash at end of period | 38.76M | 143.34M | 193.43M | 143.09M | 76.92M | 52.03M | 32.30M | 39.52M | 14.90M | 11.00M |
| Data source | Data source | Data source | Data source | Data source | Data source | Data source | Data source | Data source |